WO2016134058A1

WO2016134058A1 - Combinations useful to treat hepatitis c virus

Info

Publication number: WO2016134058A1
Application number: PCT/US2016/018327
Authority: WO
Inventors: Hui-Ju J. CHEN; David A. Degoey; Vikram KALTHOD; Allan C. Krueger; Rolf Wagner
Original assignee: Abbvie Inc.
Priority date: 2015-02-18
Filing date: 2016-02-17
Publication date: 2016-08-25

Abstract

This disclosure is directed to: (a) pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) methods for preparing such compositions; and (c) methods of use of such compositions; and (d) methods for treating HCV with a combination therapy comprising two or more anti-HCV therapeutic agents.

Description

COMBINATIONS USEFUL TO TREAT HEPATITIS C VIRUS

FIELD OF THE INVENTION

[0001] The present disclosure is directed to: (a) pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for treating hepatitis C virus (HCV); (b) methods for preparing such compositions; (c) methods of use of such compositions; and (d) methods for treating HCV with a combination therapy comprising two or more anti-HCV therapeutic agents.

BACKGROUND

[0002] Hepatitis C is a global infectious disease. About 15 to 30% of patients with chronic hepatitis C (CHC) develop cirrhosis that, on decompensation, requires liver transplantation for survival. Furthermore, CHC is associated with an increased risk for developing hepatocellular carcinoma.

[0003] Hepatitis C is caused by an RNA virus called hepatitis C virus ("HCV"), which belongs to genus Hepacivirus in family Flaviviridae . The enveloped HCV virion contains a positive stranded RNA genome encoding all known virus-specific proteins in a single, uninterrupted, open reading frame. The open reading frame comprises approximately 9500 nucleotides and encodes a single large polyprotein of about 3000 amino acids. The polyprotein comprises a core protein, envelope proteins El and E2, a membrane bound protein p7, and the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B.

[0004] At least six different HCV genotypes (with several subtypes within each genotype) are known to date. In North America, HCV genotype la predominates, followed by HCV genotypes lb, 2a, 2b, and 3a. In the United States, HCV genotypes 1, 2, and 3 are the most common, with about 80% of the hepatitis C patients having HCV genotype 1. In Europe, HCV genotype lb is predominant, followed by HCV genotypes 2a, 2b, 2c, and 3a. HCV genotypes 4 and 5 are found almost exclusively in Africa. As discussed below, the patient's HCV genotype is clinically important in determining the patient's potential response to therapy and the required duration of such therapy.

[0005] An HCV infection can cause liver inflammation (hepatitis) that is often

asymptomatic, but ensuing chronic hepatitis can result in cirrhosis of the liver (fibrotic scarring of the liver), liver cancer (hepatocellular carcinoma), and/or liver failure. Chronic HCV infection is associated with progressive liver pathology, including cirrhosis and hepatocellular carcinoma. The World Health Organization estimates that about 170 million persons worldwide are chronically infected with HCV, and from about three to about four million persons are newly infected globally each year. According to the Centers for Disease Control and Prevention, about four million people in the United States are infected with HCV. Co-infection with the human immunodeficiency virus (HIV) is common, and rates of HCV infection among HIV positive populations are higher. [0006] Most cases of acute HCV infection are not treated as the infected person either does not display symptoms or mistakes the symptoms for the flu. It is common for people to live with hepatitis C for years due to lack of symptoms. As a result, most people diagnosed with hepatitis C have had a long-term infection, or CHC.

[0007] While there is a small chance of clearing the virus spontaneously, the majority of patients with CHC will not clear the virus without treatment. Indications for treatment typically include proven HCV infection and persistent abnormal liver function tests. Viral RNA in blood is often used to confirm the presence of the virus.

[0008] Chronic hepatitis C may be treated with an interferon agent - either a "conventional" interferon or longer-acting pegylated interferon ("peg IFN") - combined with ribavirin for all genotypes. Typically, hepatitis C was treated with a combination of peg IFN-alfa and ribavirin for a period of 24 or 48 weeks, depending on the HCV genotype. Substantial limitations to efficacy and tolerability remain as many users suffer from side effects, and viral elimination from the body is often incomplete.

[0009] The goal of treatment is sustained viral response ("SVR") ~ meaning that HCV is not measurable in the patient's blood after therapy is completed. SVR12, defined as undetectable HCV RNA 12 weeks post-therapy, is recognized to be essentially a clinical cure. Following treatment with a combination of pegylated interferon alpha and ribavirin, sustained cure rates (sustained viral response) of about 75% or better occur in people with HCV genotypes 2 and 3 in 24 weeks of treatment, about 50% in those with HCV genotype 1 with 48 weeks of treatment, and about 65% in those with HCV genotype 4 in 48 weeks of treatment.

[0010] In 2011, two new oral agents, boceprevir and telaprevir received approval for treating HCV genotype 1 ("GT1"). Both agents are inhibitors of the HCV NS3/4A protease and used in combination with peg IFN and ribavirin.

[0011] Sofosbuvir, an oral uridine nucleotide prodrug inhibitor of NS5B polymerase, received approval in December 2013 for the treatment of CHC. For patients infected with HCV GT1 or GT4, the treatment regimen includes sofosbuvir in combination with peg IFN-alfa and ribavirin for a duration of twelve (12) weeks. For patients infected with HCV GT2, the treatment regimen includes sofosbuvir in combination with ribavirin for a duration of twelve (12) weeks. For patients infected with HCV GT3, the treatment regimen includes sofosbuvir in combination with ribavirin for a duration of twenty -four (24) weeks.

[0012] In late 2014, a single tablet, all oral combination of sofosbuvir and ledipasvir, a NS5A replication complex inhibitor, became available for patients infected with HCV GT1. For patients without cirrhosis, the treatment regimen includes sofosbuvir in combination with ledipasvir for a duration of twelve (12) weeks. For treatment-experienced patients with cirrhosis, the treatment regimen includes sofosbuvir in combination with ledipasvir for a duration of twenty -four (24) weeks.

[0013] Additionally, in late 2014, an all oral combination of sofosbuvir (tablet) in combination with simeprevir (capsule), an NS 3 A/4A protease inhibitor, became available for patients infected with HCV GT1. For patients without cirrhosis, the treatment regimen includes sofosbuvir in combination with simeprevir for a duration of twelve (12) weeks. For patients with cirrhosis, the treatment regimen includes sofosbuvir in combination with simeprevir for a duration of twenty -four (24) weeks.

[0014] Despite the availability of sofosbuvir, there have been many setbacks in the development of the class of nucleoside/nucleotide-based inhibitors of NS5B. Valopicitabine (NM283), a prodrug of 2 '-C-methylcytidine, was placed on clinical hold by FDA based on the overall risk/benefit profile observed in clinical testing. As a result of the clinical hold, the development of valopicitabine was discontinued. Development of PSI-352938, a P-D-2'-deoxy-2'-a-fluoro-2'-P-C- methy 1-3 ',5 '-cyclic phosphate nucleotide prodrug, was terminated due to liver enzyme elevations. BMS-986094 (ΓΝΧ-08189), a phosphoramidate prodrug of 6-0-methyl-2'-C-methyl guanosine, was discontinued from Phase 2 clinical trials (in combination with daclatasvir) in August 2012 after a drug linked patient death from cardio-renal failure (Coats, 2014). BMS-986094 was found to be an efficient substrate for human mitochondrial RNA polymerase, POLRMT (Arnold et al., 2012).

Incorporation into mitochondrial RNA may alter mitochondrial protein synthesis, thereby introducing stress on cellular energy production resulting in lactic acidosis and cardio-renal toxicity. Based on the discontinuation of BMS-986094, FDA placed a clinical hold on Idenix's NS5B inhibitors, IDX-184 and IDX-19368, which shared the same triphosphate 2'-methyl guanosine metabolite. Both agents were discontinued by Idenix thereafter. Idenix also discontinued development of IDX-20963, a uridine nucleotide prodrug, due to genotoxicity issues. VX-135 (ALS-2200), a uridine nucleotide prodrug, was placed on partial clinical hold by FDA due to observations of elevated liver enzymes in patients receiving 400mg VX-135 in combination with ribavirin. In view of these and other setbacks, the development of safe and effective nucleoside/nucleotide-based inhibitors of NS5B has been very challenging.

[0015] Considering the need for improved combinations for optimal treatment of HCV infection, including CHC, with many genotypes and wide variation in patient characteristics, there remains a strong need for combinations beyond those available.

BRIEF SUMMARY OF THE INVENTION

[0016] The present disclosure is directed to methods for treating hepatitis C in a subject in need of such treatment. In some embodiments, the subject is infected with genotype 1 HCV (HCV GT1). In some embodiments, the subject is infected with genotype 2 HCV (HCV GT2). In some embodiments, the subject is infected with genotype 3 HCV (HCV GT3). In some embodiments, the subject is infected with genotype 4 HCV (HCV GT4). In some embodiments, the subject is infected with genotype 5 HCV (HCV GT5). In some embodiments, the subject is infected with genotype 6 HCV (HCV GT6).

[0017] In at least one aspect, the methods comprise administering to a subject a combination of therapeutic agents for treating hepatitis C in the subject. In some embodiments, the methods comprise administering to the subject an amount of therapeutic agent A and an amount of therapeutic agent B; the methods may further comprise administering to the subject an amount of one or more additional therapeutic agents, such as, for example, therapeutic agent C. In some embodiments, the methods comprise administering to the subject an amount of therapeutic agent A and an amount of therapeutic agent C.

[0018] In at least one aspect, the methods comprise contacting a cell infected with HCV with a combination of therapeutic agents. In some embodiments, the methods comprise contacting a cell infected with HCV with an amount of therapeutic agent A and an amount of therapeutic agent B; the methods may further comprise contacting a cell infected with HCV with an amount of one or more additional therapeutic agents, such as, for example, therapeutic agent C. In some embodiments, the methods comprise contacting a cell infected with HCV with an amount of therapeutic agent A and an amount of therapeutic agent C.

[0019] In at least one aspect the present disclosure provides a combination therapy for treating HCV. In certain embodiments, the combination therapy comprises therapeutic agent A and therapeutic agent B. In certain embodiments, the combination therapy further comprises one or more additional therapeutic agents, such as therapeutic agent C, an inhibitor of cytochrome P-450, or ribavirin. In certain embodiments, the combination therapy further comprises therapeutic agent C and, optionally, an inhibitor of cytochrome P-450 (such as ritonavir). In some embodiments, the combination therapy comprises therapeutic agent A and therapeutic agent C.

[0020] In at least one aspect of the present disclosure, Therapeutic agent A is Compound A. Compound A has a structure corresponding to Formula A

Formula A,

wherein Ri is selected from the group consisting of hydrogen, hydroxy 1, alkyl, alkenyl, halogen and haloalkyl; and

R₂ is selected from the group consisting of hydrogen, hydroxy 1, alkyl, halogen and haloalkyl; or

Ri and R₂ and the carbon atom to which they are attached are bonded together to form a ring, wherein R₁ and R₂ are each methylene, each optionally substituted with one or two fluorine atoms; and

R₃ is selected from the group consisting of hydrogen and halogen.

[0021] In at least one aspect of the present disclosure, Ri is selected from the group consisting of hydrogen, methyl, ethynyl, hydroxy 1, fluoro, chloro, fluoromethyl, difluormethyl, trifluoromethyl.

[0022] In at least one aspect of the present disclosure, R₂ is selected from the group consisting of hydrogen, methyl, hydroxyl, fluoro, chloro, fluoromethyl, difluormethyl,

trifluoromethyl.

[0023] In at least one aspect of the present disclosure, R₃ is selected from the group consisting of hydrogen, fluoro and chloro.

[0024] In at least one aspect of the present disclosure, Ri is methyl, R₂ is hydroxyl and R₃ is hydrogen.

[0025] In at least one aspect of the present disclosure, Ri is methyl, R₂ is hydrogen and R₃ is fluoro.

[0026] In at least one aspect of the present disclosure, Ri is hydrogen, R₂ is fluoro and R₃ is fluoro.

[0027] In at least one aspect of the present disclosure, Ri is fluoro, R₂ is methyl and R₃ is fluoro.

[0028] In at least one aspect of the present disclosure, Ri is fluoro, R₂ is methyl and R₃ is hydrogen.

[0029] In at least one aspect of the present disclosure, Ri and R₂ and the carbon atom to which they are attached are bonded together to form a cyclopropyl ring, wherein R₁ is methylene and R₂ is difluromethylene; and R₃ is fluorine.

[0030] In at least one aspect of the present disclosure, Ri is trifluoromethyl, R₂ is hydroxyl and R₃ is hydrogen.

[0031] In at least one aspect of the present disclosure, therapeutic agent A is a

phosphoramidate prodrug of Compound A or a pharmaceutically acceptable salt thereof. Therapeutic agent A is selected from the group consisting of Compound A-l, Compound A-2, Compound A-3, Compound A-4, Compound A-5, and Compound A-6:

Compound A-5

Compound A-6

[0032] In certain embodiments, Therapeutic agent A is a single diastereomer of Compound A, such as a single diastereomer of compound A-l, Compound A-2 or Compound A-3, or a pharmaceutically acceptable salt thereof.

[0033] Therapeutic agent A may be combined with at least one HCV NS5A inhibitor and/or at least one HCV NS3 A inhibitor. In certain embodiments, Therapeutic agent A is combined with Therapeutic agent B. In certain embodiments, Therapeutic agent B comprises at least one HCV NS5A inhibitor. In certain embodiments, Therapeutic agent B comprises Compound B or a pharmaceutically acceptable salt thereof. Compound B is selected from the group consisting of compound B-l and compound B-2:

Compound B-2

[0034] In certain embodiments, therapeutic agent B is a pharmaceutically acceptable salt form of Compound B-1 or Compound B-2. In certain embodiments, therapeutic agent B is a pharmaceutically acceptable salt of Compound B-1. In certain embodiments, therapeutic agent B is a pharmaceutically acceptable salt of Compound B-2.

[0035] In certain embodiments, Therapeutic agent C comprises at least one HCV NS3A inhibitor or HCV protease inhibitor. In certain embodiments, Therapeutic agent C comprises compound C or a pharmaceutically acceptable salt thereof. Compound C is selected from the group consisting of compound C-1, and compound C-2:

C-1 Compound C-2

[0036] In certain embodiments, therapeutic agent C is a pharmaceutically acceptable salt form of Compound C-1 or Compound C-2. In certain embodiments, therapeutic agent C is a pharmaceutically acceptable salt of Compound C-1. In certain embodiments, therapeutic agent C is a pharmaceutically acceptable salt of Compound C-2.

[0037] In certain embodiments, ritonavir or another inhibitor of cytochrome P-450 (such as cobicistat) is administered in combination with therapeutic agent C to improve the pharmacokinetics of therapeutic agent C. In certain embodiments, the cytochrome P-450 inhibitor is ritonavir. In some embodiments, therapeutic agent C is co-administered with the cytochrome P-450 inhibitor. For instance, therapeutic agent C, such as compound C-1 or a pharmaceutically acceptable salt thereof, can be administered, for example and without limitation, concurrently with or sequentially with the cytochrome P-450 inhibitor. Therapeutic agent C can be administered immediately before or after the administration of the cytochrome P-450 inhibitor. A short delay or time gap between the administration of therapeutic agent C and the cytochrome P-450 inhibitor is also contemplated.

[0038] The present disclosure is also directed to pharmaceutical compositions comprising an amount of therapeutic agent A. In certain embodiments, the pharmaceutical compositions also include one or more additional therapeutic agents. In certain embodiments, the pharmaceutical compositions also include an additional therapeutic agent, such as therapeutic agent B; therapeutic agent C;

ribavirin and prodrugs thereof; or combinations thereof.

[0039] The present disclosure is also directed to a use of therapeutic agent A to prepare a medicament for treating hepatitis C. In certain embodiments, the medicament comprises one or more additional therapeutic agents, such as therapeutic agent B; therapeutic agent C; ribavirin and prodrugs thereof; or combinations thereof.

[0040] The medicament may be used for treating hepatitis C, inhibiting replication of an RNA virus (including HCV), or treating a disease treatable by inhibiting an RNA polymerase. [0041] The present disclosure is also directed to methods of use of therapeutic agent A, therapeutic agent B, and, optionally, therapeutic agent C to, for example, inhibit replication of a ribonucleic acid ("RNA") virus (including HCV) or treat a disease treatable by inhibiting an RNA polymerase.

[0042] The present disclosure is also directed, in part, to methods of use of the above compositions to, for example, inhibit replication of an RNA virus (including HCV) or treat a disease treatable by inhibiting an RNA polymerase.

[0043] Further benefits of the disclosed embodiments will be apparent to one skilled in the art from reading this disclosure.

DETAILED DESCRIPTION

[0044] This detailed description is intended to acquaint others skilled in the art with the disclosure, its principles, and its practical application so that those skilled in the art may adapt and apply the disclosure in its numerous forms, as they may be best suited to the requirements of a particular use. This description and its specific examples are intended for purposes of illustration only. This disclosure, therefore, is not limited to the embodiments described herein, and may be variously modified.

[0045] Where a numeric range is recited, each intervening number within the range is explicitly contemplated with the same degree of precision. For example, for the range 6 to 9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 and 7.0 are explicitly contemplated. In the same manner, all recited ratios also include all sub-ratios falling within the broader ratio.

[0046] The present disclosure is directed, in part, to methods for treating hepatitis C in a subject in need of such treatment.

[0047] In some embodiments, the methods include co-administration of an amount of therapeutic agent A and an amount of therapeutic agent B or administering an amount of therapeutic agent A with an amount of therapeutic agent B. In some embodiments, the methods further comprise administration of at least one additional therapeutic agent, such as an HCV protease inhibitor (with or without a cytochrome P-450 inhibitor such as ritonavir) or ribavirin. In some embodiments, the methods include co-administration of an amount of therapeutic agent A, an amount of therapeutic agent B, and an amount of therapeutic agent C or administering an amount of therapeutic agent A with an amount of therapeutic agent B and an amount of therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir).

[0048] In some embodiments, the methods include contacting a cell infected with HCV with an amount of therapeutic agent A and an amount of therapeutic agent B. For example, in some embodiments, the methods include contacting a cell infected with HCV with an amount of Compound A-6 and an amount of therapeutic agent B. In some embodiments, the methods further comprise contacting the cell with at least one additional therapeutic agent, such as an HCV protease inhibitor or ribavirin. In some embodiments, the methods include contacting a cell infected with HCV with an amount of therapeutic agent A, an amount of therapeutic agent B, and an amount of therapeutic agent C.

[0049] In at least one aspect of the present disclosure, Therapeutic agent A is Compound A. Compound A has a structure corresponding to Formula A

Formula A,

wherein

Ri is selected from the group consisting of hydrogen, hydroxy 1, alkyl, alkenyl, halogen and haloalkyl; and

Ri and R₂ and the carbon atom to which they are attached are bonded together to form a ring, wherein Ri and R₂ are each methylene, each optionally substituted with one or two fluorine atoms; and

R₃ is selected from the group consisting of hydrogen and halogen.

[0050] In at least one aspect of the present disclosure, Ri is selected from the group consisting of hydrogen, methyl, ethynyl, hydroxy 1, fluoro, chloro, fluoromethyl, difluormethyl, trifluoromethyl.

[0051] In at least one aspect of the present disclosure, R₂ is selected from the group consisting of hydrogen, methyl, hydroxyl, fluoro, chloro, fluoromethyl, difluormethyl,

trifluoromethyl.

[0052] In at least one aspect of the present disclosure, R₃ is selected from the group consisting of hydrogen, fluoro and chloro.

[0053] In at least one aspect of the present disclosure, Ri is methyl, R₂ is hydroxyl and R₃ is hydrogen. [0054] In at least one aspect of the present disclosure, Ri is methyl, R₂ is hydrogen and R₃ is fluoro.

[0055] In at least one aspect of the present disclosure, Ri is hydrogen, R₂ is fluoro and R₃ is fluoro.

[0056] In at least one aspect of the present disclosure, Ri is fluoro, R₂ is methyl and R₃ is fluoro.

[0057] In at least one aspect of the present disclosure, Ri is fluoro, R₂ is methyl and R₃ is hydrogen.

[0058] In at least one aspect of the present disclosure, Ri and R₂ and the carbon atom to which they are attached are bonded together to form a cyclopropyl ring, wherein Ri is methylene and R₂ is difluromethylene; and R₃ is fluorine.

[0059] In at least one aspect of the present disclosure, Ri is trifluoromethyl, R₂ is hydroxyl and R₃ is hydrogen.

[0060] In yet another aspect, any compound, salt or prodrug according to any aspect, embodiment, example and preference described herein can be isotopically substituted. Preferred isotopic substitutions include substitutions with stable or nonradioactive isotopes such as deuterium, ¹³C, ¹⁵N or ¹⁸0. Incorporation of a heavy atom, such as substitution of deuterium for hydrogen, can give rise to an isotope effect that could alter the pharmacokinetics of the drug. In one example, at least 5 mol % (e.g., at least 10 mol %) of hydrogen in a compound of the present invention is substituted with deuterium. In another example, at least 25 mole % of hydrogen in a compound of the present invention is substituted with deuterium. In a further example, at least 50, 60, 70, 80 or 90 mole % of hydrogen in a compound of the present invention is substituted with deuterium. The natural abundance of deuterium is about 0.015%. Deuterium substitution or enrichment can be achieved, without limitation, by either exchanging protons with deuterium or by synthesizing the molecule with enriched or substituted starting materials. Other methods known in the art can also be used for isotopic substitutions.

[0061] Therapeutic agent A is selected from the group consisting of compound A-1 or a salt thereof, compound A-2 or a salt thereof, compound A-3 or a salt thereof, compound A-4 or a salt thereof, compound A-5 or a salt thereof, and compound A-6 or a salt thereof:

Compound A-1

Compound A-5

Compound A-6

[0062] In certain embodiments, therapeutic agent A is a single diastereomer of Compound., Compound A-2 or Compound A-3) or a pharmaceutically acceptable salt thereof. [0063] Compound A-l is also known as (2R)-isopropyl 2-(((((2R,3R,4R,5R)-5-(2,4-dioxo- 3,4-dihydropyrimidin-l(2H)-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2- yl)methoxy)(phenoxy)phosphoryl)amino)propanoate. The synthesis and formulation of compound A-

1 are described in, for example, WO2000/018775, WO2005/012327, and WO2006/121820, the contents of which are incorporated herein by reference in their entirety.

[0064] Compound A-2 is also known as (R)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4- dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2- yl)methoxy)(phenoxy)phosphoryl)amino)propanoate. The synthesis and formulation of compound A-

2 are described in, for example, WO2000/018775, WO2005/012327, and WO2006/121820 the contents of which are incorporated herein by reference in their entirety.

[0065] Compound A-3 is also known as (R)-isopropyl 2-(((R)-(((2R,3R,4R,5R)-5-(2,4- dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2- yl)methoxy)(phenoxy)phosphoryl)amino)propanoate. The synthesis and formulation of compound A-

3 are described in, for example, WO2000/018775, WO2005/012327, and WO2006/121820 the contents of which are incorporated herein by reference in their entirety.

[0066] Compound A-4 is also known as ((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin- l(2H)-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methyl dihydrogen phosphate. The synthesis and formulation of compound A-4 are described in, for example, WO2000/018775, WO2005/012327, and WO2006/121820 the contents of which are incorporated herein by reference in their entirety.

[0067] Compound A-5 is also known as ((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin- l(2H)-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methyl trihydrogen diphosphate. The synthesis and formulation of compound A-5 are described in, for example, WO2000/018775, WO2005/012327, and WO2006/121820 the contents of which are incorporated herein by reference in their entirety.

[0068] Compound A-6 is also known as((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin- l(2H)-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate. The synthesis and formulation of compound A-6 are described in, for example, WO2000/018775, WO2005/012327, and WO2006/121820 the contents of which are incorporated herein by reference in their entirety.

[0069] Therapeutic agent A may provide improved treatments when combined with an HCV NS5 A inhibitor and/or an HCV NS 3 A inhibitor. In certain embodiments, the combinations and compositions described herein do require the use of ribavirin for genotype coverage, in particular, GT3, as one of the benefits.

[0070] Therapeutic agent B is selected from the group consisting of compound B-l or a pharmaceutically acceptable salt thereof and compound B-2 or a pharmaceutically acceptable salt thereof:

[0071] Compound B-1 is also known as dimethyl (2S,2'S)-l,l'-((2S,2'S)-2,2'-(4,4'- ((2S,5S)-l-(4-tert-butylphenyl)pyrrolidine-2,5,diyl)bis(4, l- pheny lene))bis(azanediy l)bis(oxomethy lene)bis(pyrrolidine-2, 1 -diy l)bis(3-methyl- 1 -oxobutane-2, 1 - diyl)dicarbamate. The synthesis and formulation of compound B-1 are described in, for example, U.S. Publication No. 2010/0317568, now U.S. Patent No. 8,691,938, and U.S. Publication No. 2012/0258909, now U.S. Patent No. 8,686,026, the contents of which are incorporated herein by reference in their entireties.

[0072] Compound B-2 is also known as dimethyl ((2S,2'S,3R,3'R)-((2S,2'S)-2,2'-(5,5'- ((2R,5R)-l-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-l-yl)phenyl)pyrrolidine-2,5-diyl)br fluoro-lH-benzo[d]imidazole-5,2-diyl))bis( yrrolidine-2,l-diyl))bis(3-methoxy-l-oxobutane-2,^ diyl))dicarbamate. Compound B-2 is a potent HCV protease inhibitor. The synthesis and formulation of Compound B-2 are described in U.S. Patent Application Publication No. 2012/0220562, the contents of which are incorporated herein by reference in its entirety.

[0073] In certain embodiments, therapeutic agent B is a pharmaceutically acceptable salt form of Compound B-1 or Compound B-2. In certain embodiments, therapeutic agent B is a pharmaceutically acceptable salt of Compound B-1. In certain embodiments, therapeutic agent B is a pharmaceutically acceptable salt of Compound B-2.

[0074] Therapeutic agent C is selected from the group consisting of compound C-1 or a pharmaceutically acceptable salt thereof and compound C-2 or a pharmaceutically acceptable salt thereof:

[0075] Compound C-1 is also known as (2R,6S,13aS,14aR,16aS,Z)-N- (cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)- 1,2,3,5,6,7,8,9, 10, 11, 13a, 14, 14a, 15,16, 16a-hexadecahydrocyclopropa[e]pyrrolo[l,2- a] [l,4]diazacyclopentadecine-14a-carboxamide. Compound C-1 is a potent HCV protease inhibitor. The synthesis and formulation of Compound C-1 are described in U.S. Patent Application Publication No. 2010/0144608, now U.S. Patent No. 8,420,596, and U.S. Patent Application Publication No. 2011/0312973, the contents of which are incorporated herein by reference in their entireties.

[0076] Compound C-2 is also a potent HCV protease inhibitor. The synthesis and formulation of Compound C-2 are described in U.S. Patent No. 8,648,037, the contents of which are incorporated herein by reference in its entirety.

[0077] In certain embodiments, therapeutic agent C is a pharmaceutically acceptable salt form of Compound C-1 or Compound C-2. In certain embodiments, therapeutic agent C is a pharmaceutically acceptable salt of Compound C-1. In certain embodiments, therapeutic agent C is a pharmaceutically acceptable salt of Compound C-2. [0078] In certain embodiments, ritonavir or another inhibitor of cytochrome P-450 (such as cobicistat) is administered in combination with therapeutic agent C to improve the pharmacokinetics of therapeutic agent C. In certain embodiments, the cytochrome 450 inhibitor is ritonavir. The synthesis and formulation of ritonavir are described, for example, in U.S. Patent Nos. 5,541,206 and 8,268,349, the contents of which are incorporated herein by reference in their entireties. In some embodiments, therapeutic agent C is co-administered with the cytochrome P-450 inhibitor. For instance, therapeutic agent C, such as compound C-l or a pharmaceutically acceptable salt thereof, can be administered, for example and without limitation, concurrently with or sequentially with the cytochrome P-450 inhibitor. Therapeutic agent C can be administered immediately before or after the administration of the cytochrome P-450 inhibitor. A short delay or time gap between the

administration of therapeutic agent C and the cytochrome P-450 inhibitor is also contemplated.

[0079] The total daily dose of the disclosed compounds or their salts (administered in single or divided doses) may typically be from about 0.001 to about 100 mg/kg, or from about 0.001 to about 30 mg/kg, or from about 0.01 to about 10 mg/kg (i.e., mg of the compound or salt per kg body weight).

[0080] Factors affecting the preferred dosage regimen include the genotype of HCV; the age, weight, sex, diet, and condition of the patient; the severity of the pathological condition;

pharmacological considerations, such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the particular compound or salt used; whether a drug delivery system is utilized; and the specific drug combination. Thus, the dosage regimen actually employed can vary widely, and therefore, can derive from the preferred dosage regimen set forth above.

[0081] Therapeutic agent A may be administered in any suitable amount such as, for example, in doses from 0.1 mg/kg to 200 mg/kg body weight, or from 0.25 mg/kg to 100 mg/kg, or from 0.3 mg/kg to 30 mg/kg. As non-limiting examples, therapeutic agent A may be administered in a total daily dose amount from 100 mg to 1000 mg, or from 100 mg to 500 mg, or from 200 mg to 400 mg or any amounts there between. In certain embodiments, the total daily dosage amount for compound A-2 is 200 mg. In certain embodiments, the total daily dosage amount for compound A-2 is 400 mg.

[0082] Therapeutic agent B may be administered in any suitable amount such as, for example, in doses from 0.1 mg/kg to 200 mg/kg body weight, or from 0.25 mg/kg to 100 mg/kg, or from 0.3 mg/kg to 30 mg/kg. As non-limiting examples, therapeutic agent B may be administered in a total daily dose amount from 5 mg to 500 mg, or from 10 mg to 30 mg, or from 25 mg to 200 mg, or from 25 mg to 50 mg or any amounts there between. In certain embodiments, the total daily dosage amount for compound B-l is 25 mg. In certain embodiments, the total daily dosage amount for compound B-2 is 15, 40, 120, or 400 mg. [0083] As non-limiting examples, therapeutic agent C may be administered in a total daily dosage amount from 50 mg to 300 mg, which includes, but is not limited to, for example, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg and suitable amounts therebetween. In certain embodiments, Compound C-l or a pharmaceutically acceptable salt thereof is administered in a total daily dosage amount from 80 mg to 180 mg or, alternatively, from 150 mg to 250 mg. In certain embodiments, Compound C-l or a pharmaceutically acceptable salt thereof is administered in a total daily dosage amount of 250 mg. In certain embodiments, Compound C-l or a pharmaceutically acceptable salt thereof is administered in a total daily dosage amount of 150 mg. In certain embodiments, Compound C-2 or a pharmaceutically acceptable salt thereof is administered in a total daily dosage amount of 100, 200, 300, 400, or 700 mg. The total daily dosage amount may be administered in one or more dosage forms and at one or more times daily. The total daily dosage amount may be administered once daily, twice daily, three times daily or at another frequency. For example, the total daily dosage amount may be divided between two dosage forms which are taken at different times during the day, thereby resulting in twice daily administration.

[0084] As non-limiting examples, a cytochrome P-450 inhibitor may be administered in a total daily dosage amount from 50 mg to 400 mg. In certain embodiments, the cytochrome 450 inhibitor (e.g., ritonavir) is administered at a daily dose of 100 mg.

[0085] In certain embodiments, the methods disclosed herein also include co-administration of ribavirin, or a pro-drug thereof, in the same or separate pharmaceutical compositions as the disclosed combination(s)/composition(s). Ribavirin may include any suitable form or formulation of ribavirin. Exemplary formulations of ribavirin include COPEGUS®, REBETOL® and RIBASPHERE®. An exemplary pro-drug of ribavirin is taribavirin having the chemical name of 1-β- D-ribofuranosyl-l,2,4-triazole-3-carboxamidine. Ribavirin and taribavirin may be administered in accordance with ribavirin and taribavirin administration well known in the art. In some embodiments, COPEGUS® or REBETOL® is administered in a daily dosage amount from 500 mg to 1500 mg in one dose or in divided doses. In some embodiments, COPEGUS® or REBETOL® is administered in a daily dosage amount of 800 mg. In some embodiments, REBETOL® is administered in a daily dosage amount of 1000 mg. In some embodiments, COPEGUS® or REBETOL® is administered in a daily dosage amount of 1200 mg. In some embodiments, REBETOL® is administered in a daily dosage amount of 1400 mg. Suitable dosages of ribavirin are dependent on the weight of the subject, for example 1000-1200 mg. Suitable total daily dosages of ribavirin include, but are not limited to 400 mg to 1400 mg a day, alternatively 800 mg to 1400 mg per day, alternatively 400 mg to 1200 mg, alternatively 800 mg to 1200 mg.

[0086] Dosage unit compositions may contain such amounts or submultiples thereof to make up the total daily dose. The administration of the therapeutic agent may be repeated a plurality of times. Multiple doses per day may be used to achieve the total daily dose, if desired. [0087] Therapeutic agent A may be administered at any suitable frequency and may be administered substantially simultaneous with, or independent from, therapeutic agent B. In certain embodiments, therapeutic agent A is administered at least three times daily (e.g., every 8 hours in a 24-hour period), at least two times daily (e.g., every 12 hours in a 24-hour period), or at least once daily (e.g., once in a 24-hour period). In certain embodiments, therapeutic agent A is administered once daily.

[0088] Therapeutic agent B may be administered at any suitable frequency and may be administered substantially simultaneous with, or independent from, therapeutic agent A. In certain embodiments, therapeutic agent B is administered at least three times daily (e.g., every 8 hours in a 24-hour period), at least two times daily (e.g., every 12 hours in a 24-hour period), or at least once daily (e.g., once in a 24-hour period). In certain embodiments, therapeutic agent B is administered once daily.

[0089] In certain embodiments, therapeutic agent C may be administered at any suitable frequency and may be administered substantially simultaneous with, or independent from, therapeutic agent A and/or therapeutic agent B. In certain embodiments, therapeutic agent C is administered at least three times daily (e.g., every 8 hours in a 24-hour period), at least two times daily (e.g., every 12 hours in a 24-hour period), or at least once daily (e.g., once in a 24-hour period). In certain embodiments, therapeutic agent C is administered once daily.

[0090] Therapeutic agent A, therapeutic agent B, and, optionally, therapeutic agent C, may be administered for any suitable period such as at least about 8 weeks, at least about 12 weeks, or at least about 24 weeks. In certain embodiments, therapeutic agent A and therapeutic agent B are administered for not more than 24 weeks. In certain embodiments, therapeutic agent A and therapeutic agent B are administered for not more than 12 weeks. In certain embodiments, therapeutic agent A and therapeutic agent B are administered for not more than 8 weeks. In certain embodiments, therapeutic agent A and therapeutic agent B are administered for 24 weeks. In certain embodiments, therapeutic agent A and therapeutic agent B are administered for 12 weeks. In certain embodiments, therapeutic agent A and therapeutic agent B are administered for 8 weeks.

[0091] In certain embodiments, therapeutic agent A, therapeutic agent B, and therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir) are administered for not more than 24 weeks. In certain embodiments, therapeutic agent A, therapeutic agent B, and therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir) are administered for not more than 12 weeks. In certain embodiments, therapeutic agent A, therapeutic agent B, and therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir) are administered for not more than 8 weeks. In certain embodiments, therapeutic agent A, therapeutic agent B, and therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir) are administered for 24 weeks. In certain embodiments, therapeutic agent A, therapeutic agent B, and therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir) are administered for 12 weeks. In certain embodiments, therapeutic agent A, therapeutic agent B, and therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir) are administered for 8 weeks.

[0092] Therapeutic agent A may be co-administered to the subject in combination with therapeutic agent B and/or therapeutic agent C from the same pharmaceutical composition or from separate pharmaceutical compositions. Therapeutic agent A may be co-administered to the subject in combination with therapeutic agent B and/or therapeutic agent C in a substantially simultaneous manner (e.g., or within about 5 min of each other), in a sequential manner, or both. Likewise, therapeutic agent A, therapeutic agent B, and therapeutic agent C (with or without a cytochrome P- 450 inhibitor such as ritonavir) may be co-administered in a substantially simultaneous manner (e.g., or within about 5 min of each other), in a sequential manner, or both. It is contemplated, for example, that such combination therapies may include administering one therapeutic agent multiple times between the administrations of the other. The time period between the administration of each agent may range from a few seconds (or less) to several hours or days, and will depend on, for example, the properties of each composition and active ingredient (e.g., potency, solubility, bioavailability, half- life, and kinetic profile), as well as the condition of the patient.

[0093] In certain embodiments, therapeutic agent A, therapeutic agent B and/or therapeutic agent C are co-administered with one or more additional therapeutic agents in the same or separate pharmaceutical compositions. Such additional therapeutic agents may include, for example, other therapeutic agents used to treat hepatitis C, such as additional HCV inhibitors (e.g., HCV polymerase inhibitors and HCV protease inhibitors); ribavirin or a prodrug thereof; anti-HIV agents such as HIV protease inhibitors; and cytochrome P-450 inhibitors (e.g., ritonavir or a pharmaceutically acceptable salt thereof). In certain embodiments, therapeutic agent A and therapeutic agent B are co-administered with therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir) in the same or separate pharmaceutical compositions.

[0094] In certain embodiments, therapeutic agent A, therapeutic agent B, and, optionally therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir) are coadministered with ribavirin or a pro-drug thereof, such as taribavirin, in the same or separate pharmaceutical compositions.

[0095] In certain embodiments, therapeutic agent A, therapeutic agent B, and, optionally therapeutic agent C are co-administered with an HIV inhibitor (e.g., an HIV protease inhibitor), with or without a cytochrome P-450 inhibitor (e.g., ritonavir), in the same or separate pharmaceutical compositions. [0096] In certain embodiments, the disclosed compound(s)/composition(s), and additional therapeutic agent(s) may be administered in a substantially simultaneous manner (e.g., or within about 5 min of each other), in a sequential manner, or both. It is contemplated that such combination therapies may include administering one therapeutic agent multiple times between the administrations of the other. The time period between the administration of each agent may range from a few seconds (or less) to several hours or days, and will depend on, for example, the properties of each composition and active ingredient (e.g., potency, solubility, bioavailability, half-life, and kinetic profile), as well as the condition of the patient.

[0097] The present disclosure is also directed, in part, to pharmaceutical compositions comprising one or more compounds for use in the disclosed combinations. Combination therapies provided herein include pharmaceutical compositions comprising therapeutic agent A, therapeutic agent B, and/or therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir).

[0098] In certain embodiments, a pharmaceutical composition comprises an amount of therapeutic agent A and an amount of therapeutic agent B. The amount of therapeutic agent A and therapeutic agent B may be any suitable amount that provides the desired total periodic dosing amount such as the total daily dosing amount. For example, in certain embodiments, the pharmaceutical composition comprises about 5 mg to about 30 mg (free base equivalent weight) of Compound B-l or a pharmaceutically acceptable salt thereof,

[0099] In certain embodiments, a pharmaceutical composition comprises an amount of therapeutic agent A. In certain embodiments, the pharmaceutical composition comprises a single diastereomer of Compound A-l (e.g., Compound A-2 or Compound A- 3) or a pharmaceutically acceptable salt thereof. For example, a single diastereomer is present in the pharmaceutical composition at a concentration of greater than 99% compared to the total concentration of the other diastereomers. In other embodiments, the pharmaceutical composition can include a mixture of diastereomers of Compound A-l, or a pharmaceutically acceptable salt thereof. For example, the pharmaceutical composition can include a concentration of one diastereomer of >50%, >60%, >70%, >80%, >90%, >95%, or >98% as compared to the total concentration of the other diastereomers. In some embodiments, the pharmaceutical composition includes a 1 : 1 mixture of two diastereomers of Compound A-l or a pharmaceutically acceptable salt thereof.

[00100] In certain embodiments, the pharmaceutical composition comprises Compound A-2 or a pharmaceutically acceptable salt thereof. In certain embodiments, Compound A-2 or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at a concentration of greater than 99% compared to the total concentration of the other diastereomers. In certain embodiments, Compound A-2 or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at a concentration of >50%, >60%, >70%, >80%, >90%, >95%, or >98% compared to the total concentration of the other diastereomers. [00101] In certain embodiments, the pharmaceutical composition comprises Compound A-3 or a pharmaceutically acceptable salt thereof. In certain embodiments, Compound A-3 or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at a concentration of greater than 99% compared to the total concentration of the other diastereomers. In certain embodiments, Compound A-3 or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at a concentration of >50%, >60%, >70%, >80%, >90%, >95%, or >98% compared to the total concentration of the other diastereomers.

[00102] In certain embodiments, a pharmaceutical composition comprises an amount of therapeutic agent A, therapeutic agent B, and, optionally, therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir).

[00103] In certain embodiments, a pharmaceutical composition comprises therapeutic agent B, therapeutic agent C, and, optionally, a cytochrome P-450 inhibitor, such as ritonavir. For example, in certain embodiments, the pharmaceutical composition comprises (i) about 5 mg to about 30 mg (free base equivalent weight) of Compound B-1 or a pharmaceutically acceptable salt thereof, (ii) about 40 mg to about 180 mg (free acid equivalent weight) of Compound C-l or a pharmaceutically acceptable salt thereof, and (iii) about 25 mg to about 120 mg (free base equivalent weight) of ritonavir or a pharmaceutically acceptable salt thereof. In another example, the pharmaceutical composition comprises (i) about 5 mg to about 15 mg (free base equivalent weight) of Compound B-1 or a pharmaceutically acceptable salt thereof, (ii) about 40 mg to about 90 mg (free acid equivalent weight) of Compound C-l or a pharmaceutically acceptable salt thereof, and (iii) about 25 mg to about 60 mg (free base equivalent weight) of ritonavir or a pharmaceutically acceptable salt thereof. In still another example, the pharmaceutical composition comprises (i) about 12.5 mg (free base equivalent weight) of Compound B-1, (ii) about 75 mg (free acid equivalent weight) of Compound C- 1, and (iii) about 50 mg (free base equivalent weight) of ritonavir.

[00104] In certain embodiments, a pharmaceutical composition comprising therapeutic agent B, therapeutic agent C, and a cytochrome P-450 inhibitor, such as ritonavir, includes, for example, Compounds B-1, C-l, and ritonavir at a weight ratio (free acid or free base) of about 3:2:24 to about 60:3:5 (Compound B-l :Compound C-l ritonavir). In certain embodiments, the weight ratio is about 10: 1 :2 to about 2: 1 :3 (Compound B-l :Compound C-l ritonavir). In certain embodiments, the weight ratio is about 6: 1 :4 (Compound B-l :Compound C-l ritonavir).

[00105] In certain embodiments, a dosage form comprises therapeutic agent B, therapeutic agent C, and ritonavir in the form of an amorphous solid dispersion. In one embodiment, separate amorphous solid dispersions are prepared for each of Compound B-1, Compound C-l, and ritonavir (e.g., individual mono-extrudates) and the separate amorphous solid dispersions are used to prepare the dosage form. In another embodiment, a single amorphous solid dispersion comprising Compound B-1, Compound C-l, and ritonavir (e.g., a co-extrudate) is prepared and used to prepare the dosage form.

[00106] In some embodiments, a single unit dosage form can be provided containing therapeutic agent A, therapeutic agent B, and, optionally, therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir). In some embodiments, a single unit dosage form contains Compound A-2 or a pharmaceutically acceptable salt thereof and Compound B-1 or a pharmaceutically acceptable salt thereof. In certain embodiments, the single unit dosage form further contains Compound C-l and ritonavir.

[00107] In some embodiments, two unit dosage forms can be provided, with a first unit dosage form containing therapeutic agent A and a second unit dosage form containing therapeutic agent B and, optionally, therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir). In some embodiments, the first unit dosage form contains Compound A-2 or a pharmaceutically acceptable salt thereof, and the second unit dosage form contains Compound B-1 or a pharmaceutically acceptable salt thereof. In certain embodiments, the second unit dosage form further contains Compound C-l and ritonavir.

[00108] In some embodiments, three unit dosage forms can be provided, with a first unit dosage form containing therapeutic agent A, a second unit dosage form containing therapeutic agent B, and a third unit dosage form containing therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir). In some embodiments, the first unit dosage form contains Compound A-2 or a pharmaceutically acceptable salt thereof, the second unit dosage form contains Compound B-1 or a pharmaceutically acceptable salt thereof, and the third unit dosage form contains Compound C-l and ritonavir.

[00109] In certain embodiments, the disclosed compositions comprise one or more conventional pharmaceutically acceptable carriers, adjuvants, and/or vehicles (together referred to as "excipients"). The compositions can comprise one or more additional therapeutic agents in addition to therapeutic agent A and therapeutic agent B. Such therapeutic agents can, but need not be, additional HCV inhibitors. The disclosed compositions may be prepared in a form for oral administration such as in a solid dosage form. Such solid dosage forms include, for example, capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds or salts may be combined with one or more excipients. If administered per os, the compounds or salts may be mixed with, for example, lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation, as may be provided in, for example, a dispersion of the compound or its salt in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms also may comprise buffering agents, such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. In addition, tablets and pills may be prepared with enteric coatings or other

sustained/delayed/controlled release excipients known in the art.

[00110] In certain embodiments, a dosage form comprises about 12.5 mg of Compound B-l, about 75 mg of Compound C-l, and about 50 mg of ritonavir, all of which are co-formulated with a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant in amorphous solid dispersion, wherein the polymer in the amorphous solid dispersion ranges from about 50% to about 70% by weight relative to the total weight of the amorphous solid dispersion, and the surfactant in the amorphous solid dispersion ranges from about 5% to about 15% by weight relative to the total weight of the amorphous solid dispersion. In one aspect, the polymer is copovidone, and the surfactant is vitamin E TPGS. In another aspect, the amorphous solid dispersion further comprises from about 1% to about 5% by weight of propylene glycol monolaurate, relative to the total weight of the amorphous solid dispersion. In another aspect, the amorphous solid dispersion further comprises from about 1% to about 3% by weight of propylene glycol monolaurate.

[00111] In certain embodiments, therapeutic agent C is co-formulated with a cytochrome 450 inhibitor such as ritonavir in a single dosage form. Non-limiting examples of suitable dosage forms include liquid or solid dosage forms. The dosage form may be a solid dosage form described in U.S. Publication No. 2011/0312973, entitled "Solid Compositions", the entire contents of which is incorporated herein by reference. For example, the dosage form may be a solid dosage form in which therapeutic agent C is molecularly dispersed in a matrix which comprises a pharmaceutically acceptable water-soluble polymer and a pharmaceutically acceptable surfactant. The cytochrome 450 inhibitor can also be molecularly dispersed in the matrix, or formulated in different form(s). As a non- limiting alternative, therapeutic agent C and the cytochrome 450 inhibitor can be formulated in two different dosage forms which can be provided as a combination to a subject.

[00112] In certain embodiments, the combinations or pharmaceutical compositions also comprise other therapeutic agents and combinations thereof, used to treat hepatitis C, such as any suitable amount of ribavirin and pro-drugs thereof, direct-acting antivirals (DAAs) including HCV inhibitors such as, for example, HCV helicase inhibitors, HCV polymerase inhibitors, HCV protease inhibitors, HCV NS5A inhibitors, CD81 inhibitors, cyclophilin inhibitors, or internal ribosome entry site (IRES) inhibitors; and HIV inhibitors. In certain embodiments, the combination or pharmaceutical composition comprises an amount of therapeutic agent A, an amount of therapeutic agent B, and an amount of an HCV protease inhibitor (with or without a cytochrome P-450 inhibitor such as ritonavir). In certain embodiments, the combination or pharmaceutical composition comprises an amount of therapeutic agent A, an amount of therapeutic agent B, and an amount of ribavirin. In certain embodiments, the combination or pharmaceutical composition comprises an amount of therapeutic agent A, an amount of therapeutic agent B, and an amount of therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir). In certain embodiments, the combination or pharmaceutical composition comprises an amount of therapeutic agent A, an amount of therapeutic agent B, an amount of HCV protease inhibitor (with or without a cytochrome P-450 inhibitor such as ritonavir), and ribavirin. In certain embodiments, the combination or pharmaceutical composition comprises an amount of therapeutic agent A, an amount of therapeutic agent B, an amount of therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir), and ribavirin.

[00113] In another aspect, the present invention features methods of using any of the combination of, or pharmaceutical compositions comprising, therapeutic agent A, therapeutic agent B, and/or therapeutic agent C, optionally in combination with a cytochrome P-450 inhibitor such as ritonavir to treat HCV infection. The method comprises administering an effective amount of such a combination to an HCV patient in need thereof. In one embodiment, the patient is infected with HCV genotype 1. In another embodiment, the patient is infected with HCV genotype 2. In yet another embodiment, the patient is infected with HCV genotype 3. In yet another embodiment, the patient is infected with HCV genotype 4. In yet another embodiment, the patient is infected with HCV genotype 5. In yet another embodiment, the patient is infected with HCV genotype 6.

[00114] It is contemplated that different disclosed combinations may have different anti-viral activities and/or toxicity /safety profiles. Combinations with less antiviral activities can be dosed more frequently and/or with greater amounts. Combinations with higher antiviral activities can be dosed less frequently and/or with lesser amounts. Moreover, a combination that does not have a commercially desired toxicity /safety profile does not prevent its utility under patent law as an antiviral agent, despite the fact that the US FDA might not approve it for human treatment due to the agency's benefit-cost analyses and/or other non-patent related concerns.

[00115] In yet another aspect, the present invention features methods for treating HCV infection in a subject in need of such treatment. The methods comprise administering therapeutic agent A in combination with at least one of therapeutic agent B, therapeutic agent C and DAAs to the subject for a duration of no more than 12 weeks, or for another duration as set forth herein. Such combination may comprise (1) therapeutic agent A according to any aspect, embodiment, example and preference described herein, and (2) another DAA. The other DAA can be, for example, selected from an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV NS5A inhibitor, or a cyclophilin inhibitor. Preferably, the other DAA is an HCV protease inhibitor, an HCV polymerase inhibitor, or an HCV NS5A inhibitor. More preferably, the other DAA is an HCV NS5A inhibitor, such as those described in US Patent Application Publication Nos. 2010/0317568 and 2012/0004196, both of which are incorporated herein by reference in their entireties. Highly preferably, the other DAA is the compound of Example 35 of US Patent Application Publication No. 2010/0317568. Also, highly preferably, the other DAA is the compound of Example 3.52 of US Patent Application Publication No. 2012/0004196. In one example, the duration of the treatment is 12 weeks. The duration of the treatment can also be, for example, no more than 8 weeks. Preferably, the combination is administered in amounts effective to provide a sustained virological response (SVR) or achieve another desired measure of effectiveness in the subject. The subject is not administered ribavirin during the treatment regimen. The subject is also not administered interferon during the treatment regimen. Put another way, the methods exclude the administration of interferon or ribavirin to the subject, thereby avoiding the side effects associated with interferon and ribavirin.

[00116] In another aspect, the present invention features methods for treating a population of subjects having HCV infection. The methods comprise administering therapeutic agent A in combination with at least one of therapeutic agent B, therapeutic agent C and DAAs to the subjects for a duration of no more than 12 weeks. Such combination comprises (1) therapeutic agent A according to any aspect, embodiment, example and preference described herein, and (2) another DAA. The other DAA can be, for example, selected from an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV NS5 A inhibitor, or a cyclophilin inhibitor. Preferably, the other DAA is an HCV protease inhibitor, an HCV polymerase inhibitor, or an HCV NS5A inhibitor. More preferably, the other DAA is an HCV NS5 A inhibitor, such as those described in US Patent

Application Publication Nos. 2010/0317568 and 2012/0004196, both of which are incorporated herein by reference in their entireties. Highly preferably, the other DAA is the compound of Example 35 of US Patent Application Publication No. 2010/0317568. Also, highly preferably, the other DAA is the compound of Example 3.52 of US Patent Application Publication No. 2012/0004196. Preferably, said combination is administered to the subjects in amounts effective to result in SVR or another measure of effectiveness in at least about 70% of the population, preferably at least about 80% of the population, or more preferably at least about 90% of the population. The subjects are not administered ribavirin during the treatment regimen. The subjects are also not administered interferon during the treatment regimen. Put another way, the methods exclude the administration of interferon or ribavirin to the subject, thereby avoiding the side effects associated with interferon and ribavirin.

[00117] Non-limiting examples of the other DAAs include PSI-7977 (sofosbuvir), PSI-938, BMS-790052 (daclatasvir), BMS-650032 (asunaprevir), BMS-791325, GS-5885 (ledipasvir), GS- 9451 (tegobuvir), GS-9190, GS-9256, BI-201335, BI-27127, telaprevir, VX-222, TMC-435

(simepravir), MK-5172, MK-7009 (vaniprevir ), danoprevir, paritaprevir, ombitasvir, ABT-493, and R7128 (mericitabine).

[00118] In any method described herein, the combination can be administered in any effective dosing schemes and/or frequencies; for example, they can each be administered daily. Each component of the combination can be administered either separately or in combination, and each component can be administered once a day, twice a day, or three times a day. Preferably, the components of the combination employed herein are administered once daily. [00119] In yet another aspect, the present invention features a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C according to any aspect, embodiment, example and preference described herein, and another DAA, for use to treat HCV infection. The other DAA can be, for example, selected from an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV NS5 A inhibitor, or a cyclophilin inhibitor. Preferably, the other DAA is an HCV protease inhibitor, an HCV polymerase inhibitor, or an HCV NS5A inhibitor. More preferably, the other DAA is an HCV NS5 A inhibitor, such as those described in US Patent Application Publication Nos. 2010/0317568 and 2012/0004196, both of which are incorporated herein by reference in their entireties. Highly preferably, the other DAA is the compound of Example 35 of US Patent Application Publication No. 2010/0317568. Also, highly preferably, the other DAA is the compound of Example 3.52 of US Patent Application Publication No. 2012/0004196. The treatment comprises administering the combination to a subject infected with HCV. The duration of the treatment regimen is no more than twelve weeks (e.g., the duration being 12 weeks; or the duration being 11, 10, 9, 8, 7, 6, 5, 4, or 3 weeks). Preferably, the duration of the treatment regimen is twelve weeks. The duration of the treatment can also last, for example, no more than eight weeks (e.g., the duration being 8 weeks; or the duration being 7, 6, 5, 4, or 3 weeks). The treatment does not include administering interferon or ribavirin. The combination can be administered concurrently or sequentially. Preferably, the combination is administered once daily. As a non-limiting example, the patient being treated is infected with HCV genotype 1, such as genotype la or lb. As another non- limiting example, the patient is infected with HCV genotype 2. As another non-limiting example, the patient is infected with HCV genotype 3. As another non-limiting example, the patient is infected with HCV genotype 4. As another non-limiting example, the patient is infected with HCV genotype 5. As another non-limiting example, the patient is infected with HCV genotype 6. As yet another non-limiting example, the patient is a HCV-treatment naive patient, a HCV-treatment experienced patient, an interferon non-responder (e.g., a null responder), or not a candidate for interferon treatment. As used in this application, the interferon non-responder patients include partial interferon responders and interferon rebound patients. See GUIDANCE FOR INDUSTRY - CHRONIC HEPATITIS C VIRUS INFECTION: DEVELOPING DIRECT-ACTING ANTIVIRAL AGENTS FOR TREATMENT (FDA, September 2010, draft guidance) for the definitions of naive, partial responder, responder relapser (i.e., rebound), and null responder patients. The interferon non-responder patients also include null responder patients. In one example of this aspect of the invention, the treatment lasts for 12 weeks, and the subject being treated is a naive patient infected with HCV genotype 1. In another example, the treatment lasts for 11 weeks, and the subject being treated is a naive patient infected with HCV genotype 1. In still another example, the treatment lasts for 10 weeks, and the subject being treated is a naive patient infected with HCV genotype 1. In yet another example, the treatment lasts for 9 weeks, and the subject being treated is a naive patient infected with HCV genotype 1. In yet another example, the treatment lasts for 8 weeks, and the subject being treated is a naive patient infected with HCV genotype 1. In yet another example, the treatment lasts for 7 weeks, and the subject being treated is a naive patient infected with HCV genotype 1. In yet another example, the treatment lasts for 6 weeks, and the subject being treated is a naive patient infected with HCV genotype 1. In yet another example, the treatment lasts for 5 weeks, and the subject being treated is a naive patient infected with HCV genotype 1. In yet another example, the treatment lasts for 4 weeks, and the subject being treated is a naive patient infected with HCV genotype 1. In yet another example, the treatment lasts for 3 weeks, and the subject being treated is a naive patient infected with HCV genotype 1. In yet another example, the treatment lasts for 12 weeks, and the subject being treated is a naive patient infected with HCV genotype. In another example, the treatment lasts for 11 weeks, and the subject being treated is a naive patient infected with HCV selected from genotypes 2, 3, 4, 5 or 6. In still another example, the treatment lasts for 10 weeks, and the subject being treated is a naive patient infected with HCV selected from genotypes 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 9 weeks, and the subject being treated is a naive patient infected with HCV selected from genotypes 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 8 weeks, and the subject being treated is a naive patient infected with selected from genotypes 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 7 weeks, and the subject being treated is a naive patient infected with selected from genotypes 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 6 weeks, and the subject being treated is a naive patient infected with selected from genotypes 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 5 weeks, and the subject being treated is a naive patient infected with selected from genotypes 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 4 weeks, and the subject being treated is a naive patient infected with selected from genotypes 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 3 weeks, and the subject being treated is a naive patient infected with selected from genotypes 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 12 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV genotype 1. In another example, the treatment lasts for 11 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV genotype 1. In still another example, the treatment lasts for 10 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV genotype 1. In yet another example, the treatment lasts for 9 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV genotype 1. In yet another example, the treatment lasts for 8 weeks, and the subject being treated is a non- responder (e.g., a null responder) infected with HCV genotype 1. In yet another example, the treatment lasts for 7 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV genotype 1. In yet another example, the treatment lasts for 6 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV genotype 1. In yet another example, the treatment lasts for 5 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV genotype 1. In yet another example, the treatment lasts for 4 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV genotype 1. In yet another example, the treatment lasts for 3 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV genotype 1. In yet another example, the treatment lasts for 12 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV selected from genotype 2, 3, 4, 5 or 6. In another example, the treatment lasts for 11 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV selected from genotype 2, 3, 4, 5 or 6. In still another example, the treatment lasts for 10 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV selected from genotype 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 9 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV selected from genotype 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 8 weeks, and the subject being treated is a non- responder (e.g., a null responder) infected with HCV selected from genotype 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 7 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV selected from genotype 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 6 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV selected from genotype 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 5 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV selected from genotype 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 4 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV selected from genotype 2, 3, 4, 5 or 6. In yet another example, the treatment lasts for 3 weeks, and the subject being treated is a non-responder (e.g., a null responder) infected with HCV selected from genotype 2, 3, 4, 5 or 6.

[00120] A treatment regimen of the present invention generally constitutes a complete treatment regimen, i.e., no subsequent interferon-containing regimen is intended. Thus, a treatment or use described herein generally does not include any subsequent interferon-containing treatment. Preferably, a treatment or use described herein does not include any subsequent ribavirin-containing treatment.

[00121] The methods of the present invention can provide effective treatment of HCV infection without the use of interferon or ribavirin and for a shorter period of time, for example and without limitation, a treatment duration of no more than twelve weeks, alternatively no more than eleven weeks, alternatively no more than ten weeks, alternatively no more than nine weeks, alternatively no more than eight weeks, alternatively no more than seven weeks, alternatively no more than six weeks, alternatively no more than five weeks, alternatively no more than four weeks, or alternatively, no more than three weeks. [00122] In one aspect, the present invention features methods for treating HCV infection in a subject comprising administering therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C, and DAAs, in the absence of interferon and ribavirin, to the subject for a duration of no more than twelve weeks, alternatively no more than eight weeks. Put another way, the methods exclude interferon and ribavirin. Said combination comprises therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C according to any aspect, embodiment, example and preference described herein, and another DAA, which can be co-administered, or administered separately or independently, with the same or different dosing frequencies. Preferably, said combination is administered once a day. They can also be administered, for example, twice a day or three times a day. The other DAA can be, for example, selected from an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV NS5A inhibitor, or a cyclophilin inhibitor. Preferably, the other DAA is an HCV protease inhibitor, an HCV polymerase inhibitor, or an HCV NS5A inhibitor. More preferably, the other DAA is an HCV NS5 A inhibitor, such as those described in US Patent

Application Publication Nos. 2010/0317568 and 2012/0004196. Highly preferably, the other DAA is the compound of Example 35 of US Patent Application Publication No. 2010/0317568. Also, highly preferably, the other DAA is the compound of Example 3.52 of US Patent Application Publication No. 2012/0004196.

[00123] Various measures may be used to express the effectiveness of a method of the present invention. One such measure is SVR, which, as used herein, means that the virus is undetectable at the end of therapy and for at least 8 weeks after the end of therapy (SVR8); preferably, the virus is undetectable at the end of therapy and for at least 12 weeks after the end of therapy (SVR12); more preferably, the virus is undetectable at the end of therapy and for at least 16 weeks after the end of therapy (SVR 16); and highly preferably, the virus is undetectable at the end of therapy and for at least 24 weeks after the end of therapy (SVR24). SVR24 is often considered as a functional definition of cure; and a high rate of SVR at less than 24 week post-treatment (e.g., SVR8 or SVR12) can be predictive of a high rate of SVR24.

[00124] In some embodiments, a treatment regimen of the invention comprises treating a population of subjects having HCV infection (e.g. treatment naive subjects), and the regimen comprises administering therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs to the subjects for a duration of no more than 12 weeks, or for another duration disclosed herein, wherein said combination comprises therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C according to any aspect, embodiment, example and preference described herein, and another DAA, and are administered to the subjects in amounts effective to provide an SVR (e.g., SVR12 or SVR24) in at least about 70% of the population, alternatively at least about 75% of the population, alternatively at least about 80% of the population, alternatively at least about 85% of the population, alternatively at least about 90% of the population, alternatively at least about 95% of the population, alternatively about 100% of the population. The other DAA can be, for example, selected from an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV NS5A inhibitor, or a cyclophilin inhibitor. Preferably, the other DAA is an HCV protease inhibitor, an HCV polymerase inhibitor, or an HCV NS5 A inhibitor. More preferably, the other DAA is an HCV NS5A inhibitor, such as those described in US Patent Application Publication Nos. 2010/0317568 and 2012/0004196. Highly preferably, the other DAA is the compound of Example 35 of US Patent Application Publication No. 2010/0317568. Also, highly preferably, the other DAA is the compound of Example 3.52 of US Patent Application Publication No.

2012/0004196.

[00125] In some embodiments, a treatment regimen of the invention comprises treating a population of IFN experienced subjects (e.g., interferon non-responders) having HCV infection, and the method comprises administering therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs to the subjects for a duration of no more than 12 weeks, or for another duration disclosed herein, wherein said at least two DAAs comprise (1) therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C according to any aspect, embodiment, example and preference described herein, and another DAA, and are administered to the subjects in amounts effective to provide an SVR (e.g., SVR12 or SVR24) in at least about 50% of the population, alternatively at least about 55% of the population, alternatively at least about 60% of the population, alternatively at least about 65% of the population, alternatively at least about 70% of the population, alternatively at least about 75% of the population, alternatively at least about 80% of the population, alternatively at least about 85% of the population, alternatively at least about 90% of the population, alternatively at least about 95% of the population, or alternatively about 100% of the population.

[00126] In any aspect, embodiment, example and preference described herein, the one or more DAAs can be, for example, selected from an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV NS5A inhibitor, or a cyclophilin inhibitor. Preferably, the one or more DAAs is an HCV protease inhibitor, an HCV polymerase inhibitor, or an HCV NS5 A inhibitor. More preferably, the one or more DAAs is an HCV NS5 A inhibitor, such as those described in US Patent Application Publication Nos. 2010/0317568 and 2012/0004196. Highly preferably, the one or more DAAs is the compound of Example 35 of US Patent Application Publication No. 2010/0317568. Also, highly preferably, the one or more DAAs is the compound of Example 3.52 of US Patent Application Publication No. 2012/0004196.

[00127] In one aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 8 weeks and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-re sponder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to Compound 1 and Compound 2, said at least two DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5 A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS-9190, GS-9451, BI-201335, BI-207127, telaprevir, VX- 222, mericitabine, and danoprevir.

[00128] In another aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 7 weeks and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-re sponder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to Compound 1 and Compound 2, said at least two DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5 A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS-9190, GS-9451, BI-201335, BI-207127, telaprevir, VX- 222, mericitabine, and danoprevir.

[00129] In yet another aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 6 weeks and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-responder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs, said DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS- 9190, GS-9451, BI-201335, BI-207127, telaprevir, VX-222, mericitabine, and danoprevir.

[00130] In yet another aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 5 weeks and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-responder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs, said DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS- 9190, GS-9451, BI-201335, BI-207127, telaprevir, VX-222, mericitabine, and danoprevir.

[00131] In yet another aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 4 weeks and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-responder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs, said DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS- 9190, GS-9451, BI-201335, BI-207127, telaprevir, VX-222, mericitabine, and danoprevir.

[00132] In yet another aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 3 weeks and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-re sponder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs, said DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS- 9190, GS-9451, BI-201335, BI-207127, telaprevir, VX-222, mericitabine, and danoprevir.

[00133] In yet another aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 24 weeks and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-re sponder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs, said DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS- 9190, GS-9451, BI-201335, BI-207127, telaprevir, VX-222, mericitabine, and danoprevir. [00134] In yet another aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 13 to 23 weeks (e.g., the duration of the treatment is selected from 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 weeks) and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-re sponder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs, said DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS- 9190, GS-9451, BI-201335, BI-207127, telaprevir, VX-222, mericitabine, and danoprevir.

[00135] In yet another aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 12 weeks and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-re sponder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs, said DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS- 9190, GS-9451, BI-201335, BI-207127, telaprevir, VX-222, mericitabine, and danoprevir. As used in this application, a HCV polymerase inhibitor can be a nucleoside polymerase inhibitor, a nucleotide polymerase inhibitor, a non-nucleoside polymerase inhibitor, or a non-nucleotide polymerase inhibitor. [00136] In yet another aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 11 weeks and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-re sponder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs, said DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS- 9190, GS-9451, BI-201335, BI-207127, telaprevir, VX-222, mericitabine, and danoprevir.

[00137] In yet another aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 10 weeks and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-re sponder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs, said DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS- 9190, GS-9451, BI-201335, BI-207127, telaprevir, VX-222, mericitabine, and danoprevir.

[00138] In yet another aspect, the present invention features a method of treating HCV infection, comprising administering to a patient in need thereof an effective amount of a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. The treatment lasts 9 weeks and does not include administration of any interferon or ribavirin. The DAAs can be administered at the same or different dosing frequencies. The patient being treated can be a treatment naive patient; a treatment experienced patient, including, but not limited to, a relapser, an interferon partial responder, an interferon non-re sponder, or a null responder; or a patient unable to take interferon. The patient may be infected with, for example and without limitation, HCV genotype 1, such as HCV genotype la or HCV genotype lb; or HCV genotype 2 or 3; or HCV genotype 4, 5 or 6. The treatment according to this aspect of the technology may also be effective against other HCV genotypes. The DAAs can be administered around the same time or at different times. In addition to therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs, said DAAs can also include one or more additional DAAs selected from, for example, HCV protease inhibitors, HCV polymerase inhibitors, or HCV NS5A inhibitors. Non-limiting examples of such additional DAAs include PSI-7977, PSI-938, TMC-435, BMS-790052, BMS-650032, GS-5885, GS- 9190, GS-9451, BI-201335, BI-207127, telaprevir, VX-222, mericitabine, and danoprevir.

[00139] A method of the present invention can be used to treat a naive patient or a treatment experienced patient. Treatment experienced patients include interferon non-responders (e.g., null responders), partial responders, and relapsers. A method of the present invention can also be used to treat patients who are not candidates for interferon treatment. Patients who are not candidates for interferon treatment include, but are not limited to, one or more of the following groups: patients intolerant to interferon, patients who refuse to take interferon treatment, patients with medical conditions which preclude them from taking interferon, and patients who have an increased risk of side effects or infection by taking interferon.

[00140] In any method described herein, one or more additional DAAs can be optionally used in the treatment regimen in addition to therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs. These additional DAAs can be HCV protease inhibitors, HCV nucleoside or nucleotide polymerase inhibitors, HCV non-nucleoside polymerase inhibitors, HCV NS3B inhibitors, HCV NS4A inhibitors, HCV NS5 A inhibitors, HCV NS5B inhibitors, HCV entry inhibitors, cyclophilin inhibitors, or combinations thereof.

[00141] Preferred HCV protease inhibitors for this purpose include, but are not limited to, telaprevir (Vertex), boceprevir (Merck), BI-201335 (Boehringer Ingelheim), GS-9451 (Gilead), and BMS-650032 (BMS). Other suitable protease inhibitors include, but are not limited to, ACH-1095 (Achillion), ACH-1625 (Achillion), ACH-2684 (Achillion), AVL-181 (Avila), AVL-192 (Avila), BMS-650032 (BMS), danoprevir (RG7227/ITMN-191, Roche), GS-9132 (Gilead), GS-9256 (Gilead), IDX-136 (Idenix), IDX-316 (Idenix), IDX-320 (Idenix), MK-5172 (Merck), narlaprevir (Schering- Plough Corp), PHX-1766 (Phenomix), TMC-435 (Tibotec), vaniprevir (MK-7009, Merck), VBY708 (Virobay), VX-500 (Vertex), VX-813 (Vertex), VX-985 (Vertex), or a combination thereof. [00142] Preferred non-nucleoside HCV polymerase inhibitors for use in the present invention include, but are not limited to, GS-9190 (Gilead), BI-207127 (Boehringer Ingelheim), and VX-222 (VCH-222) (Vertex & ViraChem). Preferred nucleotide HCV polymerase inhibitors include, but are not limited to, PSI-7977 (Gilead), and PSI-938 (Gilead). Other suitable and non-limiting examples of suitable HCV polymerase inhibitors include ANA-598 (Anadys), BI-207127 (Boehringer Ingelheim), BILB-1941 (Boehringer Ingelheim), BMS-791325 (BMS), filibuvir, GL59728 (Glaxo), GL60667 (Glaxo), GS-9669 (Gilead), IDX-375 (Idenix), MK-3281 (Merck), tegobuvir, TMC-647055 (Tibotec), VCH-759 (Vertex & ViraChem), VCH-916 (ViraChem), VX-759 (Vertex), GS-6620 (Gilead), IDX- 102 (Idenix), IDX-184 (Idenix), ΓΝΧ-189 (Inhibitex), MK-0608 (Merck), RG7128 (Roche),

TMC64912 (Medivir), GSK625433 (GlaxoSmithKline), BCX-4678 (BioCryst), ALS-2200 (Alios BioPharma/Vertex), ALS-2158 (Alios BioPharma/Vertex), or a combination thereof. A polymerase inhibitor may be a nucleoside or nucleotide polymerase inhibitor, such as GS-6620 (Gilead), IDX-102 (Idenix), IDX-184 (Idenix), INX-189 (Inhibitex), MK-0608 (Merck), PSI-7977 (Gilead), PSI-938 (Gilead), RG7128 (Roche), TMC64912 (Medivir), ALS-2200 (Alios BioPharma/Vertex), ALS-2158 (Alios BioPharma/Vertex), or a combination therefore. A polymerase inhibitor may also be a non- nucleoside polymerase inhibitor, such as PF-00868554 (Pfizer), ANA-598 (Anadys), BI-207127 (Boehringer Ingelheim), BILB-1941 (Boehringer Ingelheim), BMS-791325 (BMS), filibuvir, GL59728 (Glaxo), GL60667 (Glaxo), GS-9669 (Gilead), IDX-375 (Idenix), MK-3281 (Merck), tegobuvir (Gilead),, TMC-647055 (Tibotec), VCH-759 (Vertex & ViraChem), VCH-916 (ViraChem), VX-222 (VCH-222) (Vertex & ViraChem), VX-759 (Vertex), or a combination thereof.

[00143] Preferred NS5A inhibitors include, but are not limited to, BMS-790052 (BMS) and GS-5885 (Gilead). Non-limiting examples of suitable NS5A inhibitors include GSK62336805 (GlaxoSmithKline), ACH-2928 (Achillion), AZD2836 (Astra-Zeneca), AZD7295 (Astra-Zeneca), BMS-790052 (BMS), BMS-824393 (BMS), GS-5885 (Gilead), PPI-1301 (Presidio), PPI-461 (Presidio) A-831 (Arrow Therapeutics), A-689 (Arrow Therapeutics) or a combination thereof.

[00144] Non-limiting examples of suitable cyclophilin inhibitors include alisporovir (Novartis & Debiopharm), NM-811 (Novartis), SCY-635 (Scynexis), or a combination thereof.

[00145] Non-limiting examples of suitable HCV entry inhibitors include ITX-4520 (iTherx), ITX-5061 (iTherx), or a combination thereof.

[00146] Specific examples of other DAA agents that are suitable for inclusion in a method of the present invention include, but are not limited to, AP-H005, A-831 (Arrow Therapeutics) (NS5A inhibitor), A-689 (Arrow Therapeutics) (NS5A inhibitor), ΓΝΧ08189 (Inhibitex) (polymerase inhibitor), ITMN-191 (Intermune/Roche) (NS3/4A Protease inhibitor), VBY-376 (Protease Inhibitor) (Virobay), ACH-1625 (Achillion, Protease inhibitor), IDX136 (Idenix, Protease Inhibitor), IDX316 (Idenix, Protease inhibitor), VX-813 (Vertex), SCH 900518 (Schering-Plough), TMC-435 (Tibotec), ITMN-191 (Intermune, Roche), MK-7009 (Merck), IDX-PI (Novartis), R7128 (Roche), PF-868554 (Pfizer) (non-nucleoside polymerase inhibitor), PF-4878691 (Pfizer), IDX-184 (Idenix), IDX-375 (Idenix, NS5B polymerase inhibitor), PPI-461 (Presidio), BILB-1941 (Boehringer Ingelheim), GS- 9190 (Gilead), BMS-790052 (BMS), CTS-1027 (Conatus), GS-9620 (Gilead), PF-4878691 (Pfizer), RO5303253 (Roche), ALS-2200 (Alios BioPharma/Vertex), ALS-2158 (Alios BioPharma/Vertex), GSK62336805 (GlaxoSmithKline), or any combinations thereof.

[00147] In some embodiments, the present invention features methods for treating patients infected with HCV genotype 1, such as la or lb. The methods comprise administering to such a patient a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs for no more than 12 weeks (e.g., the duration being 12 weeks), such as no more than 8 weeks (e.g., the duration being 8 weeks), wherein the treatment does not include administration of either interferon or ribavirin, therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs can be administered in therapeutically effective amounts to provide a SVR (for example, SVR12 or SVR24) after the completion of the treatment. The patients may be treatment naive patients or treatment experienced patients. The treatment duration can be no more than 12 weeks, including but not limited to, no more than 11 weeks, no more than 10 weeks, no more than 9 weeks, but preferably no more than 8 weeks, no more than 7 weeks, no more than 6 weeks, no more than 5 weeks, no more than 4 weeks, or no more than 3 weeks, e.g., the duration being 12 weeks, or the duration being 8 weeks.

[00148] In some embodiments, the present invention features methods for treating patients with HCV genotype 2 or 3 infection. The methods comprise administering to such a patient a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs for no more than 12 weeks (e.g., the duration being 12 weeks), such as no more than 8 weeks (e.g., the duration being 8 weeks), wherein the treatment does not include administration of either interferon or ribavirin, therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs can be administered in therapeutically effective amounts to provide a SVR (for example, SVR 12 or SVR24) after the completion of the treatment. The patients may be treatment naive patients or treatment experienced patients. The treatment duration can be no more than 12 weeks, including but not limited to, no more than 11 weeks, no more than 10 weeks, no more than 9 weeks, but preferably no more than 8 weeks, no more than 7 weeks, no more than 6 weeks, no more than 5 weeks, no more than 4 weeks, or no more than 3 weeks, e.g., the duration being 12 weeks, or the duration being 8 weeks.

[00149] In some embodiments, the present invention features methods for treating patients with HCV genotype 2 infection. The methods comprise administering to such a patient a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs for no more than 12 weeks (e.g., the duration being 12 weeks), such as no more than 8 weeks (e.g., the duration being 8 weeks), wherein the treatment does not include administration of either interferon or ribavirin, therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs can be administered in therapeutically effective amounts to provide a SVR (for example, SVR12 or SVR24) after the completion of the treatment. The patients may be treatment naive patients or treatment experienced patients. The treatment duration can be no more than 12 weeks, including but not limited to, no more than 11 weeks, no more than 10 weeks, no more than 9 weeks, but preferably no more than 8 weeks, no more than 7 weeks, no more than 6 weeks, no more than 5 weeks, no more than 4 weeks, or no more than 3 weeks, e.g., the duration being 12 weeks, or the duration being 8 weeks.

[00150] In some embodiments, the present invention features methods for treating patients with HCV genotype 3 infection. The methods comprise administering to such a patient a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs for no more than 12 weeks (e.g., the duration being 12 weeks), such as no more than 8 weeks (e.g., the duration being 8 weeks), wherein the treatment does not include administration of either interferon or ribavirin, therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs can be administered in therapeutically effective amounts to provide a SVR (for example, SVR12 or SVR24) after the completion of the treatment. The patients may be treatment naive patients or treatment experienced patients. The treatment duration can be no more than 12 weeks, including but not limited to, no more than 11 weeks, no more than 10 weeks, no more than 9 weeks, but preferably no more than 8 weeks, no more than 7 weeks, no more than 6 weeks, no more than 5 weeks, no more than 4 weeks, or no more than 3 weeks, e.g., the duration being 12 weeks, or the duration being 8 weeks.

[00151] In some embodiments, the present invention features methods for treating patients with HCV genotype 4 infection. The methods comprise administering to such a patient a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs for no more than 12 weeks (e.g., the duration being 12 weeks), such as no more than 8 weeks (e.g., the duration being 8 weeks), wherein the treatment does not include administration of either interferon or ribavirin, therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs can be administered in therapeutically effective amounts to provide a SVR (for example, SVR12 or SVR24) after the completion of the treatment. The patients may be treatment naive patients or treatment experienced patients. The treatment duration can be no more than 12 weeks, including but not limited to, no more than 11 weeks, no more than 10 weeks, no more than 9 weeks, but preferably no more than 8 weeks, no more than 7 weeks, no more than 6 weeks, no more than 5 weeks, no more than 4 weeks, or no more than 3 weeks, e.g., the duration being 12 weeks, or the duration being 8 weeks. [00152] In some embodiments, the present invention features methods for treating patients with HCV genotype 5 infection. The methods comprise administering to such a patient a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs for no more than 12 weeks (e.g., the duration being 12 weeks), such as no more than 8 weeks (e.g., the duration being 8 weeks), wherein the treatment does not include administration of either interferon or ribavirin, therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs can be administered in therapeutically effective amounts to provide a SVR (for example, SVR12 or SVR24) after the completion of the treatment. The patients may be treatment naive patients or treatment experienced patients. The treatment duration can be no more than 12 weeks, including but not limited to, no more than 11 weeks, no more than 10 weeks, no more than 9 weeks, but preferably no more than 8 weeks, no more than 7 weeks, no more than 6 weeks, no more than 5 weeks, no more than 4 weeks, or no more than 3 weeks, e.g., the duration being 12 weeks, or the duration being 8 weeks.

[00153] In some embodiments, the present invention features methods for treating patients with HCV genotype 6 infection. The methods comprise administering to such a patient a combination of therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs for no more than 12 weeks (e.g., the duration being 12 weeks), such as no more than 8 weeks (e.g., the duration being 8 weeks), wherein the treatment does not include administration of either interferon or ribavirin, therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs can be administered in therapeutically effective amounts to provide a SVR (for example, SVR12 or SVR24) after the completion of the treatment. The patients may be treatment naive patients or treatment experienced patients. The treatment duration can be no more than 12 weeks, including but not limited to, no more than 11 weeks, no more than 10 weeks, no more than 9 weeks, but preferably no more than 8 weeks, no more than 7 weeks, no more than 6 weeks, no more than 5 weeks, no more than 4 weeks, or no more than 3 weeks, e.g., the duration being 12 weeks, or the duration being 8 weeks.

[00154] It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the disease undergoing therapy.

[00155] In any method described herein, therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs may be co-formulated in a single dosage form. Non-limiting examples of suitable dosage forms include liquid or solid dosage forms. Preferably, therapeutic agent A with at least one of therapeutic agent B, therapeutic agent C and DAAs are formulated in a single solid dosage form in which at least one of the components is in an amorphous form, or highly preferably molecularly dispersed, in a matrix which comprises a pharmaceutically acceptable water- soluble polymer and a pharmaceutically acceptable surfactant. The other components can also be in an amorphous form or molecularly dispersed in the matrix, or formulated in different form(s) (e.g., in a crystalline form). More preferably, each of the components is in an amorphous form, or highly preferably molecularly dispersed, in a matrix which comprises a pharmaceutically acceptable water- soluble polymer and a pharmaceutically acceptable surfactant.

[00156] In any method described herein, the patient being treated can be a treatment-naive patient.

[00157] In any method described herein, the patient being treated can be an interferon non- responder.

[00158] In any method described herein, the patient being treated can be an interferon null- responder.

[00159] In any method described herein, the patient being treated can be without cirrhosis.

[00160] In any method described herein, the patient being treated can be a cirrhotic patient.

[00161] In any method described herein, the patient being treated can be a patient with compensated cirrhosis.

[00162] The present disclosure is also directed, in part, to a method for inhibiting replication of an RNA virus. In certain embodiments, the disclosed combination(s)/composition(s) is used in a method for inhibiting replication of an RNA virus. In certain embodiments, the methods comprise exposing the virus to one or more of the disclosed combination(s)/composition(s). In certain embodiments, replication of the RNA virus is inhibited in vitro. In certain embodiments, replication of the RNA virus is inhibited in vivo. In certain embodiments, the RNA virus whose replication is being inhibited is a single -stranded, positive sense RNA virus. In some such embodiments, the RNA virus whose replication is being inhibited is a virus from the family Flaviviridae. In some such embodiments, the RNA virus whose replication is being inhibited is HCV. In certain embodiments, the methods comprise administering the disclosed combination(s)/composition(s) to a patient infected with an RNA virus, such as HCV. In certain embodiments, therapeutic agent A is administered in combination with therapeutic agent B to inhibit replication of an RNA virus. In certain embodiments, therapeutic agent A and therapeutic agent B are administered in the same or separate pharmaceutical compositions to inhibit replication of an RNA virus. In certain embodiments, therapeutic agent A is administered in combination with therapeutic agent B and at least one additional therapeutic agent, such as an HCV protease inhibitor (with or without a cytochrome P-450 inhibitor such as ritonavir) or ribavirin, to inhibit replication of an RNA virus. In certain embodiments, therapeutic agent A is administered in combination with therapeutic agent B and therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir) to inhibit replication of the RNA virus. In certain embodiments, the methods comprise contacting a cell infected with an RNA virus, such as HCV, with an effective amount of a combination of compounds described herein. In certain embodiments, the methods comprise contacting a cell infected with an RNA virus, such as HCV, with an amount of therapeutic agent A and an amount of therapeutic agent B effective to inhibit replication of the RNA virus. In certain embodiments, the methods comprise contacting a cell infected with an RNA virus, such as HCV, with a combination of therapeutic agent A, therapeutic agent B, and at least one additional therapeutic agent, such as an HCV protease inhibitor or ribavirin, to inhibit replication of the RNA virus. In certain embodiments, the methods comprise contacting a cell infected with an RNA virus, such as HCV, with an effective amount of a combination of therapeutic agent A, therapeutic agent B, and therapeutic agent C to inhibit replication of the RNA virus.

[00163] The present disclosure is also directed, in part, to a method for inhibiting activity of an HCV protein, such as HCV NS5B polymerase, HCV NS5A, and/or HCV protease. In certain embodiments, the disclosed combination(s)/composition(s) is used in a method for inhibiting an HCV protein. In certain embodiments, activity of an HCV protein is inhibited in vitro. In certain embodiments, activity of an HCV protein is inhibited in vivo. In certain embodiments, the methods comprise administering the disclosed combination(s)/composition(s) to a patient infected with HCV. In certain embodiments, therapeutic agent A is administered in combination with therapeutic agent B to inhibit activity of an HCV protein. In certain embodiments, therapeutic agent A and therapeutic agent B are administered in the same or separate pharmaceutical compositions to inhibit activity of an HCV protein. In certain embodiments, therapeutic agent A is administered in combination with therapeutic agent B and at least one additional therapeutic agent, such as an HCV protease inhibitor (with or without a cytochrome P-450 inhibitor such as ritonavir) or ribavirin, to inhibit activity of an HCV protein. In certain embodiments, therapeutic agent A is administered in combination with therapeutic agent B and therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir) to inhibit activity of an HCV protein. In certain embodiments, the methods comprise contacting a cell infected with HCV with an effective amount of a combination of compounds described herein. In certain embodiments, the methods comprise contacting a cell infected with HCV with an amount of therapeutic agent A and an amount of therapeutic agent B effective to inhibit activity of an HCV protein. In certain embodiments, the methods comprise contacting a cell infected with HCV with a combination of therapeutic agent A, therapeutic agent B, and at least one additional therapeutic agent, such as an HCV protease inhibitor or ribavirin, to inhibit activity of an HCV protein. In certain embodiments, the methods comprise contacting a cell infected with HCV with an effective amount of a combination of therapeutic agent A, therapeutic agent B, and therapeutic agent C to inhibit activity of an HCV protein.

[00164] The term "inhibiting" refers to reducing the level of RNA virus replication/HCV protein activity either in vitro or in vivo. For example, if a disclosed combination(s)/composition(s) reduces the level of RNA virus replication by at least about 10% compared to the level of RNA virus replication before the virus was exposed to the combination(s)/composition(s), then the

combination(s)/ composition(s) inhibits RNA virus replication. In some embodiments, the disclosed combination(s)/ composition(s) can inhibit RNA virus replication by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95%.

[00165] The present disclosure is also directed, in part, to a method for treating a disease that can be treated by inhibiting HCV NS5A and/or HCV NS5B proteins. Thus, this disclosure is also directed, in part, to a method for treating hepatitis C in an animal in need of such treatment. In certain embodiments, these methods comprise administering to the animal a disclosed

combination(s)/composition(s). In certain embodiments, a therapeutically effective amount of the disclosed combination(s)/composition(s) is administered to the animal. In certain embodiments, therapeutic agent A is administered in combination with therapeutic agent B to treat hepatitis C. In certain embodiments, therapeutic agent A is administered in combination with therapeutic agent B and at least one additional therapeutic agent, such as an HCV protease inhibitor (with or without a cytochrome P-450 inhibitor such as ritonavir) or ribavirin, to treat hepatitis C. In certain

embodiments, therapeutic agent A is administered in combination with therapeutic agent B and therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir), to treat hepatitis C. In certain embodiments, the methods comprise contacting a cell infected with HCV with an effective amount of a combination of compounds described herein to treat hepatitis C. In certain embodiments, the methods comprise contacting a cell infected with HCV with an amount of therapeutic agent A and an amount of therapeutic agent B effective to treat hepatitis C. In certain embodiments, the methods comprise contacting a cell infected with HCV with a combination of therapeutic agent A, therapeutic agent B, and at least one additional therapeutic agent, such as an HCV protease inhibitor or ribavirin, to treat hepatitis C. In certain embodiments, the methods comprise contacting a cell infected with HCV with an effective amount of a combination of therapeutic agent A, therapeutic agent B, and therapeutic agent C to treat hepatitis C.

[00166] The term "treating" refers to ameliorating, suppressing, eradicating, preventing, reducing the risk of, and/or delaying the onset of the disease being treated. The term "treating" encompasses administration of the disclosed combination(s)/composition(s) to an HCV-negative patient that is a candidate for an organ transplant.

[00167] The methods of treatment are particularly suitable for use with humans, but may be used with other animals, particularly mammals. A "therapeutically -effective amount" or "effective amount" is an amount that will achieve the goal of treating the targeted condition. [00168] In certain embodiments, a combination of therapeutic agent A and therapeutic agent B is used to decrease HCV viral load in a patient infected with HCV. In certain embodiments, therapeutic agent A is administered in combination with therapeutic agent B and, optionally, at least one additional therapeutic agent, as an HCV protease inhibitor (with or without a cytochrome P-450 inhibitor such as ritonavir) or ribavirin, to decrease HCV viral load. In certain embodiments, cells infected with HCV are contacted with therapeutic agent A and therapeutic agent B and, optionally, at least one additional therapeutic agent, as an HCV protease inhibitor or ribavirin, to decrease HCV viral load. For example, if a disclosed combination(s)/composition(s) reduces the HCV viral load by at least about 10% compared to the HCV viral load before the virus was exposed to the

combination(s)/composition(s), then the combination(s)/composition(s) reduces the HCV viral load. In some embodiments, the disclosed combination(s)/composition(s) can reduce viral load by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95%.

[00169] The present disclosure is also directed, in part, to use of therapeutic agents A and B, and, optionally, one or more additional therapeutic agents, to prepare a medicament. In some embodiments, the above medicaments are for co-administration with one or more additional therapeutic agents. In some embodiments, the medicaments are for inhibiting replication of an RNA virus. In some embodiments, the disclosed medicaments are for inhibiting HCV RNA polymerase activity. In some embodiments, the medicaments are for treating hepatitis C.

[00170] The present disclosure is directed, in part, to methods comprising combination therapy for HCV infection, wherein therapeutic agent A is combined with therapeutic agent B and, optionally, one or more additional therapeutic agents, such as, for example, ribavirin or pro-drugs thereof or an HCV protease inhibitor, to treat HCV infection.

[00171] In at least one aspect, therapeutic agent A is combined with therapeutic agent B to treat HCV infection. In some embodiments, Compound A-1 is combined with Compound B-1 to treat HCV infection. In some embodiments, Compound A-1 is combined with Compound B-2 to treat HCV infection. In some embodiments, Compound A-2 is combined with Compound B ■l to treat HCV infection. In some embodiments, Compound A-2 is combined with Compound B ■2 to treat HCV infection. In some embodiments, Compound A-3 is combined with Compound B ■l to treat HCV infection. In some embodiments, Compound A-3 is combined with Compound B ■2 to treat HCV infection. In some embodiments, Compound A-4 is combined with Compound B ■l to treat HCV infection. In some embodiments, Compound A-4 is combined with Compound B ■2 to treat HCV infection. In some embodiments, Compound A-5 is combined with Compound B ■l to treat HCV infection. In some embodiments, Compound A-5 is combined with Compound B ■2 to treat HCV infection. In some embodiments, Compound A-6 is combined with Compound B ■l to treat HCV infection. In some embodiments, Compound A-6 is combined with Compound B-2 to treat HCV infection.

[00172] In at least one aspect, therapeutic agent A is combined with therapeutic agent B and therapeutic agent C (with or without a cytochrome P-450 inhibitor such as ritonavir) to treat HCV infection. In some embodiments, Compound A-l is combined with Compound B-1 and Compound C-

1 to treat HCV infection. In some embodiments, Compound A-l is combined with Compound B-2 and Compound C-1 to treat HCV infection. In some embodiments, Compound A-l is combined with Compound B-1 and Compound C-2 to treat HCV infection. In some embodiments, Compound A-l is combined with Compound B-2 and Compound C-2 to treat HCV infection. In some embodiments, Compound A-2 is combined with Compound B-1 and Compound C-1 to treat HCV infection. In some embodiments, Compound A-2 is combined with Compound B-2 and Compound C-1 to treat HCV infection. In some embodiments, Compound A-2 is combined with Compound B-1 and Compound C-

2 to treat HCV infection. In some embodiments, Compound A-2 is combined with Compound B-2 and Compound C-2 to treat HCV infection. In some embodiments, Compound A-3 is combined with Compound B-1 and Compound C-1 to treat HCV infection. In some embodiments, Compound A-3 is combined with Compound B-2 and Compound C-1 to treat HCV infection. In some embodiments, Compound A-3 is combined with Compound B-1 and Compound C-2 to treat HCV infection. In some embodiments, Compound A-3 is combined with Compound B-2 and Compound C-2 to treat HCV infection. In some embodiments, Compound A-4 is combined with Compound B-1 and Compound C-

1 to treat HCV infection. In some embodiments, Compound A-4 is combined with Compound B-2 and Compound C-1 to treat HCV infection. In some embodiments, Compound A-4 is combined with Compound B-1 and Compound C-2 to treat HCV infection. In some embodiments, Compound A-4 is combined with Compound B-2 and Compound C-2 to treat HCV infection. In some embodiments, Compound A-5 is combined with Compound B-1 and Compound C-1 to treat HCV infection. In some embodiments, Compound A-5 is combined with Compound B-2 and Compound C-1 to treat HCV infection. In some embodiments, Compound A-5 is combined with Compound B-1 and Compound C-

2 to treat HCV infection. In some embodiments, Compound A-5 is combined with Compound B-2 and Compound C-2 to treat HCV infection. In some embodiments, Compound A-6 is combined with Compound B-1 and Compound C-1 to treat HCV infection. In some embodiments, Compound A-6 is combined with Compound B-2 and Compound C-1 to treat HCV infection. In some embodiments, Compound A-6 is combined with Compound B-1 and Compound C-2 to treat HCV infection. In some embodiments, Compound A-6 is combined with Compound B-2 and Compound C-2 to treat HCV infection.

[00173] All references (patent and non-patent) cited above are incorporated by reference into this patent application. The discussion of those references is intended merely to summarize assertions made by their authors. No admission is made that any reference (or a portion of a reference) is relevant prior art (or prior art at all). Applicants reserve the right to challenge the accuracy and pertinence of the cited references.

[00174] The foregoing description of the present invention provides illustration and description, but is not intended to be exhaustive or to limit the invention to the precise one disclosed. Modifications and variations are possible in light of the above teachings or may be acquired from practice of the invention. Thus, it is noted that the scope of the invention is defined by the claims and their equivalents.

Claims

CLAIMS:

1. A pharmaceutical composition comprising an amount of therapeutic agent A and an amount of therapeutic agent B, wherein therapeutic agent A is selected from the group consisting of compound A-1 or a salt thereof, compound A-2 or a salt thereof, and compound A-3 or a salt thereof:

Compound A-1

Compound A-2 (S_P isomer)

Compound A-3 (R_P isomer)

and therapeutic agent B is selected from the group consisting of compound B-1 or a pharmaceutically acceptable salt thereof and compound B-2 or a pharmaceutically acceptable salt thereof:

2. A method for treating hepatitis C in a subject in need of such treatment, the method comprising: administering to the subject an amount of therapeutic agent A and an amount of therapeutic agent B, wherein therapeutic agent A is selected from the group consisting of compound A-1 or a salt thereof, compound A-2 or a salt thereof, and compound A-3 or a salt thereof:

Compound A-1

Compound A-2 (S_P isomer)

Compound A-3 (R_P isomer)

3. The method of claim 1, wherein therapeutic agent A is Compound A-l .

4. The method of claim 1, wherein therapeutic agent A is Compound A-2.

5. The method of claim 1, wherein therapeutic agent B is Compound B-1.

6. The method of claim 1, wherein therapeutic agent B is Compound B-2.

7. The method of claim 1, wherein the amount of therapeutic agent A administered to the subject is from about 50 to about 500 mg.

8. The method of claim 1, wherein therapeutic agent A is administered orally.

9. The method of claim 1, further comprising administering to the subject an amount of therapeutic agent C, wherein therapeutic agent C is selected from is selected from the group consisting of compound C-1 or a pharmaceutically acceptable salt thereof and compound C-2 or a pharmaceutically acceptable salt thereof:

2

10. The method of claim 8, wherein therapeutic agent C is Compound C-1.

11. A method for treating hepatitis C in a subject in need of such treatment, the method comprising: contacting a cell infected with the hepatitis C virus with an amount of therapeutic agent A and an amount of therapeutic agent B, wherein therapeutic agent A is selected from the group consisting of compound A-1 or a salt thereof, compound A-2 or a salt thereof, compound A-3 or a salt thereof, compound A-4 or a salt thereof, compound A-5 or a salt thereof, and compound A-6 or a salt thereof:

Compound A-5

Compound A-6

12. The method of claim 10, wherein therapeutic agent A is Compound A-6.

13. The method of claim 10, wherein therapeutic agent B is Compound B-1.

14. The method of claim 10, wherein therapeutic agent B is Compound B-2.

15. The method of claim 10, further comprising contacting the cell with an amount of therapeutic agent C, wherein therapeutic agent C is selected from is selected from the group consisting of compound C-1 or a pharmaceutically acceptable salt thereof and compound C-2 or a pharmaceutically acceptable salt thereof:

The method of claim 14, wherein therapeutic agent C is Compound C-1.

17. The method of claim 16, wherein therapeutic agent A is Compound A-l.

18. The method of claim 16, wherein therapeutic agent A is Compound A-2.

19. The method of claim 16, wherein therapeutic agent B is Compound B-l.

20. The method of claim 16, wherein therapeutic agent B is Compound B-2.